Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
307
-
Total 13F shares, excl. options
-
94,131,376
-
Shares change
-
+5,240,549
-
Total reported value, excl. options
-
$3,423,160,510
-
Value change
-
+$191,188,547
-
Put/Call ratio
-
63%
-
Number of buys
-
167
-
Number of sells
-
-150
-
Price
-
$36.36
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2025
388 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q2 2025.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 307 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94,131,376 shares
of 95,963,102 outstanding shares and own 98% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (10,213,422 shares), BlackRock, Inc. (6,256,145 shares), SANDS CAPITAL MANAGEMENT, LLC (3,943,485 shares), JPMORGAN CHASE & CO (3,260,868 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,886,268 shares), BAKER BROS. ADVISORS LP (2,772,692 shares), FMR LLC (2,604,588 shares), STATE STREET CORP (2,572,240 shares), SUVRETTA CAPITAL MANAGEMENT, LLC (2,278,000 shares), and Clearbridge Investments, LLC (2,140,577 shares).
This table shows the top 307 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.